BRPI0413276B8 - derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica - Google Patents
derivado de insulina, complexo de zinco do mesmo, e, composição farmacêuticaInfo
- Publication number
- BRPI0413276B8 BRPI0413276B8 BRPI0413276A BRPI0413276A BRPI0413276B8 BR PI0413276 B8 BRPI0413276 B8 BR PI0413276B8 BR PI0413276 A BRPI0413276 A BR PI0413276A BR PI0413276 A BRPI0413276 A BR PI0413276A BR PI0413276 B8 BRPI0413276 B8 BR PI0413276B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- zinc complex
- insulin derivative
- insulin
- amino group
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 5
- 239000004026 insulin derivative Substances 0.000 title abstract 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000011701 zinc Substances 0.000 title abstract 2
- 229910052725 zinc Inorganic materials 0.000 title abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301129 | 2003-08-05 | ||
| DKPA200301129 | 2003-08-05 | ||
| US49545103P | 2003-08-14 | 2003-08-14 | |
| US60/495,451 | 2003-08-14 | ||
| PCT/DK2004/000511 WO2005012347A2 (en) | 2003-08-05 | 2004-07-22 | Novel insulin derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0413276A BRPI0413276A (pt) | 2006-10-10 |
| BRPI0413276B1 BRPI0413276B1 (pt) | 2020-03-03 |
| BRPI0413276B8 true BRPI0413276B8 (pt) | 2021-05-25 |
Family
ID=34117520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413276A BRPI0413276B8 (pt) | 2003-08-05 | 2004-07-22 | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7615532B2 (OSRAM) |
| EP (3) | EP2264065B1 (OSRAM) |
| JP (1) | JP4463814B2 (OSRAM) |
| KR (1) | KR101159559B1 (OSRAM) |
| AU (2) | AU2004261353B2 (OSRAM) |
| BE (2) | BE2013C035I2 (OSRAM) |
| BR (1) | BRPI0413276B8 (OSRAM) |
| CA (1) | CA2531988C (OSRAM) |
| CY (5) | CY1113850T1 (OSRAM) |
| FR (2) | FR13C0035I2 (OSRAM) |
| HU (1) | HUS1300033I1 (OSRAM) |
| IL (1) | IL172980A (OSRAM) |
| LU (2) | LU92213I2 (OSRAM) |
| MX (1) | MXPA06001283A (OSRAM) |
| NO (5) | NO340925B1 (OSRAM) |
| PL (1) | PL2107069T3 (OSRAM) |
| RU (1) | RU2518460C2 (OSRAM) |
| WO (1) | WO2005012347A2 (OSRAM) |
Families Citing this family (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2328579T3 (es) * | 2003-07-25 | 2009-11-16 | Conjuchem Biotechnologies Inc. | Derivados de insulina de larga duracion y procedimientos asociados. |
| EP2264065B1 (en) | 2003-08-05 | 2017-03-08 | Novo Nordisk A/S | Novel insulin derivatives |
| EP2256130B1 (en) * | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Novel insulin derivatives |
| ES2435522T3 (es) * | 2005-02-02 | 2013-12-20 | Novo Nordisk A/S | Derivados de insulina |
| ATE519780T1 (de) * | 2005-12-28 | 2011-08-15 | Novo Nordisk As | Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen |
| US8722620B2 (en) | 2006-02-27 | 2014-05-13 | Novo Nordisk A/S | Insulin derivatives |
| WO2007104736A2 (en) * | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| US8293965B2 (en) | 2006-04-28 | 2012-10-23 | Kimberly-Clark Worldwide, Inc. | Antimicrobial site dressings |
| ES2553154T3 (es) | 2006-05-09 | 2015-12-04 | Novo Nordisk A/S | Derivado de la insulina |
| CN101437849B (zh) * | 2006-05-09 | 2015-09-30 | 诺沃-诺迪斯克有限公司 | 胰岛素衍生物 |
| RU2451029C2 (ru) | 2006-05-09 | 2012-05-20 | Ново Нордиск А/С | Производное инсулина |
| JP5097900B2 (ja) * | 2006-06-27 | 2012-12-12 | 独立行政法人物質・材料研究機構 | 有機酸又はこれらの誘導体の活性エステル体の製造方法 |
| WO2008015099A2 (en) * | 2006-07-31 | 2008-02-07 | Novo Nordisk A/S | Pegylated, extended insulins |
| AU2007298919C1 (en) | 2006-09-22 | 2014-02-06 | Novo Nordisk A/S | Protease resistant insulin analogues |
| US9387176B2 (en) | 2007-04-30 | 2016-07-12 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
| EP2164458A1 (en) * | 2007-06-01 | 2010-03-24 | Novo Nordisk A/S | Stable non-aqueous pharmaceutical compositions |
| EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| EP2178910B1 (en) * | 2007-08-15 | 2014-10-08 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| AU2008288413B2 (en) * | 2007-08-15 | 2013-09-26 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| CN101157725B (zh) * | 2007-10-24 | 2012-07-25 | 中国药科大学 | 人胰岛素类似物的制备方法及用途 |
| EP2217621B1 (en) * | 2007-11-08 | 2015-04-22 | Novo Nordisk A/S | Insulin derivative |
| PL2209800T3 (pl) | 2007-11-16 | 2013-12-31 | Novo Nordisk As | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
| WO2009112583A2 (en) | 2008-03-14 | 2009-09-17 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
| CA2718738C (en) | 2008-03-18 | 2019-05-07 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| CN102149411A (zh) | 2008-09-12 | 2011-08-10 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| ES2607003T3 (es) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria |
| MX2011007544A (es) | 2009-01-23 | 2011-08-12 | Novo Nordisk As | Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso. |
| US8835379B2 (en) | 2009-10-30 | 2014-09-16 | Novo Nordisk A/S | Derivatives of CGRP |
| EP2523655A2 (en) | 2010-01-12 | 2012-11-21 | Novo Nordisk A/S | Pharmaceutical compositions for oral administration of insulin peptides |
| ES2582590T3 (es) | 2010-02-16 | 2016-09-13 | Novo Nordisk A/S | Método de purificación |
| JP5826772B2 (ja) | 2010-02-16 | 2015-12-02 | ノヴォ ノルディスク アー／エス | コンジュゲートタンパク質 |
| ES2612468T3 (es) | 2010-05-10 | 2017-05-17 | Novo Nordisk A/S | Procedimiento para la preparación de complejos de insulina-zinc |
| US20130345397A1 (en) | 2010-05-25 | 2013-12-26 | Andrea Robinson | Methods for the synthesis of dicarba bridges in peptides |
| US8883722B2 (en) | 2010-06-23 | 2014-11-11 | Novo Nordisk A/S | Human insulin containing additional disulfide bonds |
| US8815798B2 (en) | 2010-06-23 | 2014-08-26 | Novo Nordisk A/S | Insulin analogues containing additional disulfide bonds |
| WO2011161125A1 (en) * | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
| EP2627670A2 (en) | 2010-10-15 | 2013-08-21 | Novo Nordisk A/S | Novel n-terminally modified insulin derivatives |
| BR112013010345A2 (pt) | 2010-10-27 | 2017-07-25 | Novo Nordisk As | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção |
| KR20130139297A (ko) * | 2010-10-27 | 2013-12-20 | 노보 노르디스크 에이/에스 | 다양한 주사 간격으로 투여된 인슐린 주사를 이용한 진성 당뇨병의 치료 |
| CN103249427A (zh) | 2010-12-14 | 2013-08-14 | 诺沃—诺迪斯克有限公司 | 速效胰岛素联合长效胰岛素 |
| WO2012110422A1 (en) | 2011-02-15 | 2012-08-23 | Novo Nordisk A/S | Long-acting il-1 receptor antagonists |
| US20140031278A1 (en) * | 2011-03-28 | 2014-01-30 | Novo Nordisk A/S | Novel Glucagon Analogues |
| WO2012140155A1 (en) | 2011-04-14 | 2012-10-18 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| EP2720711A1 (en) | 2011-06-15 | 2014-04-23 | Novo Nordisk A/S | Multi substituted insulins |
| RU2017101333A (ru) * | 2011-09-23 | 2018-12-19 | Ново Нордиск А/С | Новые аналоги глюкагона |
| EP2784085A4 (en) * | 2011-12-15 | 2015-07-08 | Shanghai Hengrui Pharm Co Ltd | HUMAN INSULIN ANALOG AND ACYLATED DERIVATIVITY THEREOF |
| JP2015502971A (ja) | 2011-12-21 | 2015-01-29 | ノヴォ ノルディスク アー／エス | Ｎ末端修飾インスリン誘導体 |
| US9481721B2 (en) | 2012-04-11 | 2016-11-01 | Novo Nordisk A/S | Insulin formulations |
| US20160031962A1 (en) * | 2012-04-20 | 2016-02-04 | Kleomenis K. Barlos | Solid phase peptide synthesis of insulin using side chain achored lysine |
| BR112014026442A8 (pt) | 2012-05-01 | 2018-01-16 | Novo Nordisk As | combinação para alcançar o controle glicêmico, seu uso, e composição farmacêutica. |
| US20150111820A1 (en) | 2012-07-09 | 2015-04-23 | Novo Nordisk A/S | Novel use of insulin derivatives |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| US20150265710A1 (en) | 2012-10-17 | 2015-09-24 | Novo Nordisk A/S | Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery |
| PL2934567T3 (pl) | 2012-12-21 | 2018-10-31 | Sanofi | Pochodne eksendyny-4 jako podwójny agonista GLP1/GIP lub potrójny agonista GLP1/GIP/glukagon |
| US20160296602A1 (en) * | 2013-03-20 | 2016-10-13 | Novo Nordisk A/S | Dosing Regimen |
| BR112015025464A2 (pt) | 2013-04-18 | 2017-10-10 | Novo Nordisk As | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico |
| JP2016519127A (ja) | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー／エス | 新規投与レジメン |
| GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| WO2015052088A1 (en) | 2013-10-07 | 2015-04-16 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
| FR3013049B1 (fr) | 2013-11-14 | 2015-11-13 | You-Ping Chan | Analogue de l'insuline glargine |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| RU2016134425A (ru) | 2014-02-18 | 2018-03-20 | Ново Нордиск А/С | Стабильные аналоги глюкагона и их применение для лечения гипогликемии |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| US20180244743A1 (en) | 2015-08-25 | 2018-08-30 | Novo Nordisk A/S | Novel Insulin Derivatives and the Medical Uses Hereof |
| CN108026156A (zh) | 2015-08-25 | 2018-05-11 | 诺和诺德股份有限公司 | 新型胰岛素衍生物及其医学用途 |
| CN108463468B (zh) * | 2016-08-02 | 2022-03-04 | 江苏恒瑞医药股份有限公司 | 一种人胰岛素或其类似物的酰化衍生物 |
| WO2018096163A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications |
| WO2018096164A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| EP3544683A1 (en) | 2016-11-28 | 2019-10-02 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| ES2930149T3 (es) | 2016-12-16 | 2022-12-07 | Novo Nordisk As | Composiciones farmacéuticas que contienen insulina |
| JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| WO2019154311A1 (zh) | 2018-02-09 | 2019-08-15 | 江苏恒瑞医药股份有限公司 | 一种密码子优化的人胰岛素类似物前体基因和信号肽基因 |
| CN111601819A (zh) | 2018-05-24 | 2020-08-28 | 江苏恒瑞医药股份有限公司 | 一种重组人胰岛素或其类似物的前体的制备方法 |
| EP3815106B1 (en) | 2018-06-26 | 2024-12-25 | Novo Nordisk A/S | System providing dose recommendations for basal insulin titration |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| KR102666154B1 (ko) | 2018-08-08 | 2024-05-20 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
| KR20200080747A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법 |
| KR20200080748A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법 |
| US12343383B2 (en) | 2019-07-12 | 2025-07-01 | Novo Nordisk A/S | High concentration insulin formulation |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CA3166495A1 (en) | 2019-12-30 | 2021-07-08 | Gan & Lee Pharmaceuticals Co., Ltd. | Insulin derivative |
| PE20230832A1 (es) | 2020-05-15 | 2023-05-19 | Lilly Co Eli | Compuestos de insulina acilada de accion temporal prolongada |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| US20250000948A1 (en) | 2021-11-15 | 2025-01-02 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| WO2023143458A1 (zh) | 2022-01-28 | 2023-08-03 | 甘李药业股份有限公司 | 酰化胰岛素 |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| WO2025104600A1 (en) * | 2023-11-15 | 2025-05-22 | Ambio, Inc. | Insulin analogs for the treatment of human metabolic disorder and disease |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1212679B (de) | 1957-08-03 | 1966-03-17 | Novo Terapeutisk Labor As | Verfahren zur Herstellung von Insulinloesungen |
| GB1042194A (en) | 1962-04-30 | 1966-09-14 | Olin Mathieson | Insulin preparations |
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3868358A (en) * | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
| GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
| JPS5767548A (en) | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
| FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| US5605884A (en) * | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| DE3827533A1 (de) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
| HUT56857A (en) | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
| NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| CA2070814A1 (en) | 1989-12-21 | 1991-06-22 | Klavs H. Jorgensen | Insulin preparations containing nicotinic acid or nicotinamide |
| DK45590D0 (OSRAM) | 1990-02-21 | 1990-02-21 | Novo Nordisk As | |
| JP3193398B2 (ja) | 1991-07-23 | 2001-07-30 | サンデン株式会社 | ショ−ケ−ス |
| DK0618807T3 (da) | 1991-12-20 | 2003-03-03 | Novo Nordisk As | Stabiliseret farmaceutisk formulering omfattende human væksthormon og histidin |
| US6011007A (en) * | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6869930B1 (en) * | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| AU682061B2 (en) * | 1993-09-17 | 1997-09-18 | Novo Nordisk A/S | Acylated insulin |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| WO1996010417A1 (en) | 1994-10-04 | 1996-04-11 | Novo Nordisk A/S | PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5830999A (en) * | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
| AU720966B2 (en) | 1995-03-17 | 2000-06-22 | Novo Nordisk A/S | Insulin derivatives |
| US6251856B1 (en) * | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| SI2275119T1 (sl) | 1995-07-27 | 2013-12-31 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
| US6451970B1 (en) * | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| US5898267A (en) * | 1996-04-10 | 1999-04-27 | Mcdermott; Kevin | Parabolic axial lighting device |
| US5866538A (en) * | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5905140A (en) * | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| JP3300368B2 (ja) | 1996-07-11 | 2002-07-08 | ノボ ノルディスク アクティーゼルスカブ | 選択的アシル化方法 |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| ATE264871T1 (de) * | 1996-07-26 | 2004-05-15 | Aventis Pharma Gmbh | Insulinderivate mit erhöhter zinkbindung |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| WO1998042367A1 (en) | 1997-03-20 | 1998-10-01 | Novo Nordisk A/S | Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer |
| EP1005490B1 (en) * | 1997-03-20 | 2006-03-29 | Novo Nordisk A/S | Zinc free insulin crystals for use in pulmonary compositions |
| AU6611998A (en) | 1997-03-20 | 1998-10-20 | Novo Nordisk A/S | Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
| US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| EP1283051B1 (en) | 1997-06-13 | 2006-06-14 | Eli Lilly And Company | Stable insulin formulations |
| IL134901A0 (en) | 1997-10-24 | 2001-05-20 | Lilly Co Eli | Insoluble insulin compositions |
| US6451762B1 (en) * | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| BR9813128A (pt) * | 1997-10-24 | 2000-08-15 | Novo Nordisk As | Agregado solúvel em água de derivados de insulina, derivado de insulina, preparação farmacêutica, e, processo para tratamento de diabetes mellitus |
| US20020155994A1 (en) * | 1997-10-24 | 2002-10-24 | Svend Havelund | Aggregates of human insulin derivatives |
| ZA989744B (en) * | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| CO4970787A1 (es) | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| AU1870099A (en) * | 1998-01-09 | 1999-07-26 | Novo Nordisk A/S | Stabilised insulin compositions |
| US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| UA65636C2 (uk) | 1998-10-16 | 2004-04-15 | Ново Нордіск А/С | Стабільні концентровані препарати інсуліну для доставки через легені |
| DK2130554T3 (da) * | 1999-02-22 | 2012-12-03 | Univ Connecticut | Albuminfrie faktor VIII-præparater |
| EP1173482A1 (en) | 1999-04-27 | 2002-01-23 | Eli Lilly And Company | Insulin crystals for pulmonary administration |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US6652886B2 (en) * | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| US20030119734A1 (en) | 2001-06-28 | 2003-06-26 | Flink James M. | Stable formulation of modified GLP-1 |
| US20050014679A1 (en) | 2001-12-20 | 2005-01-20 | Beals John Michael | Insulin molecule having protracted time action |
| WO2003075950A1 (en) * | 2002-03-13 | 2003-09-18 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| ATE496064T1 (de) * | 2002-05-07 | 2011-02-15 | Novo Nordisk As | Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten |
| US20050232899A1 (en) * | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| US20040002451A1 (en) * | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
| KR100615389B1 (ko) | 2002-08-23 | 2006-08-25 | (주)헬릭서 | 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품 |
| KR20050083841A (ko) | 2002-10-29 | 2005-08-26 | 알자 코포레이션 | 안정화된 고체상태 폴리펩타이드 입자 |
| US20040138099A1 (en) * | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
| JPWO2004069259A1 (ja) | 2003-02-07 | 2006-05-25 | 味の素株式会社 | 糖尿病治療剤 |
| EP1597367B1 (en) | 2003-02-19 | 2010-07-07 | Novartis AG | Glycoprotein antigen sima135 expressed in metastatic human tumor cells |
| JP2006519252A (ja) | 2003-03-04 | 2006-08-24 | ザ・テクノロジー・デヴェロップメント・カンパニー・リミテッド | 薬物送達系および細胞療法 |
| JP4658041B2 (ja) | 2003-06-25 | 2011-03-23 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子ポリペプチドの液体組成物 |
| US20050054818A1 (en) * | 2003-07-02 | 2005-03-10 | Brader Mark Laurence | Crystalline compositions for controlling blood glucose |
| EP2264065B1 (en) * | 2003-08-05 | 2017-03-08 | Novo Nordisk A/S | Novel insulin derivatives |
| KR101186851B1 (ko) | 2003-08-05 | 2012-10-02 | 노보 노르디스크 에이/에스 | 신규의 인슐린 유도체 |
| KR101293503B1 (ko) | 2003-08-14 | 2013-08-07 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물 |
| WO2005021022A2 (en) | 2003-09-01 | 2005-03-10 | Novo Nordisk A/S | Stable formulations of peptides |
| ES2229931B1 (es) * | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
| EP1687428A1 (en) * | 2003-11-14 | 2006-08-09 | Novo Nordisk A/S | Processes for making acylated insulin |
| ATE554792T1 (de) | 2003-12-23 | 2012-05-15 | Pharmacia Corp | Stabiles wachstumshormon-flüssigformulierung |
| PL2319500T3 (pl) | 2004-03-12 | 2013-05-31 | Biodel Inc | Szybko działające kompozycje do dostarczania leku |
| ATE543506T1 (de) | 2004-06-01 | 2012-02-15 | Ares Trading Sa | Methode zur stabilisierung von proteinen |
| AU2005272862B2 (en) | 2004-08-12 | 2011-03-10 | Merck Sharp & Dohme Corp. | Stable pegylated interferon formulation |
| PT1778723E (pt) | 2004-08-17 | 2013-01-25 | Regeneron Pharma | Formulações de antagonista de il-1 |
| EP1814581B1 (en) | 2004-11-12 | 2016-03-16 | Novo Nordisk A/S | Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline |
| JP4874989B2 (ja) | 2004-11-22 | 2012-02-15 | ノヴォ ノルディスク アー／エス | 可溶性で安定なインスリン含有調合物 |
| CN101106979A (zh) | 2005-01-21 | 2008-01-16 | 阿尔扎公司 | 具有改善的稳定性的含有至少一种反离子的用于涂覆微针的治疗性的肽试剂 |
| EP2256130B1 (en) * | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Novel insulin derivatives |
| ATE519780T1 (de) | 2005-12-28 | 2011-08-15 | Novo Nordisk As | Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen |
| US8722620B2 (en) * | 2006-02-27 | 2014-05-13 | Novo Nordisk A/S | Insulin derivatives |
| CA2649109A1 (en) | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| RU2451029C2 (ru) * | 2006-05-09 | 2012-05-20 | Ново Нордиск А/С | Производное инсулина |
| WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| PL2209800T3 (pl) * | 2007-11-16 | 2013-12-31 | Novo Nordisk As | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
-
2004
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en not_active Expired - Lifetime
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/es active IP Right Grant
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/pt active IP Right Grant
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/ko not_active Expired - Lifetime
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en not_active Expired - Lifetime
- 2004-07-22 PL PL09165072T patent/PL2107069T3/pl unknown
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en active Application Filing
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/ja not_active Expired - Lifetime
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
-
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/no active Protection Beyond IP Right Term
-
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/ru active
-
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en not_active Expired - Lifetime
-
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
-
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/el unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/fr unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/xx unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/fr active Active
- 2013-07-04 CY CY2013027C patent/CY2013027PI2/el unknown
- 2013-07-05 FR FR13C0038C patent/FR13C0038I1/fr active Active
- 2013-07-08 CY CY2013029C patent/CY2013029PI2/el unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/hu unknown
-
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
-
2018
- 2018-01-11 NO NO2018003C patent/NO2018003I1/no unknown
- 2018-01-11 NO NO2018002C patent/NO2018002I2/no unknown
-
2023
- 2023-12-28 CY CY2013029C patent/CY2013029I2/el unknown
-
2024
- 2024-01-16 NO NO2024003C patent/NO2024003I1/no unknown
- 2024-01-16 NO NO2024004C patent/NO2024004I1/no unknown
- 2024-01-31 CY CY2013027C patent/CY2013027I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0413276B8 (pt) | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica | |
| SG178797A1 (en) | Oligosaccharide chain added glp-1 peptide | |
| WO2008081701A1 (ja) | Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 | |
| NZ591497A (en) | A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment | |
| PH12014500923A1 (en) | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified | |
| BR0315047A (pt) | Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto | |
| BR112014007675A2 (pt) | tratamento de doença articular degenerativa | |
| BRPI0717098B8 (pt) | análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação | |
| BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
| AR061500A1 (es) | Un agente antidiabetico para el control de la hiperglucemia diabetica y de las complicaciones relacionadas con la diabetes | |
| ATE506957T1 (de) | Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen | |
| DE60314495D1 (de) | Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern | |
| ATE513853T1 (de) | Peptide und peptidderivate sowie pharmazeutische zusammensetzungen, die diese enthalten | |
| BRPI0511421A (pt) | composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo | |
| NZ601142A (en) | Composition for improving brain function and method for improving brain function | |
| BRPI0513858A (pt) | compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa | |
| MX363119B (es) | Composicion farmaceutica. | |
| ATE443722T1 (de) | Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung | |
| BRPI0621347B8 (pt) | composição farmacêutica para aumentar a produção de eritrócitos e para o tratamento de anemia | |
| UY29498A1 (es) | Derivados de aminoácidos | |
| MX2009002962A (es) | Peptidos antibacterianos y antivirales de actinomadura namibiensis. | |
| WO2025185523A8 (zh) | 环肽及其组合物和用途 | |
| BRPI0512503A (pt) | composição que compreende ácido lático e lactoferrina | |
| ATE427956T1 (de) | Ckrox-peptide und ihre analoge zur behandlung von hautalterung | |
| PE20121553A1 (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una efermedad parasitaria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/03/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI NO 52402.001245/2022-49 ORIGEM: 13A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1087251-24.2021.4.01.3400 SUBJUDICE AUTOR: NOVO NORDISK A/S E NOVO NORDISK FARMACEUTICA DO BRASIL LTDA. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL |